# BioFront (NCT07383441)

> Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07383441
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: SWOG Cancer Research Network
- Conditions: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Axitinib; Biospecimen Collection; Bone Scan; Cabozantinib; Clostridium butyricum CBM 588 Probiotic Strain; Computed Tomography; Ipilimumab; Lenvatinib; Magnetic Resonance Imaging; Nivolumab; Nivolumab and Recombinant Human Hyaluronidase; Pembrolizumab; Placebo Administration
- Enrollment: 718
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on BioFront so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 18
- YouTube: 3
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=biofront-nct07383441

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07383441", "email": "<work email>"}; the inbox owner confirms by the emailed link.